Vaspin and lipocalin-2 levels in severe obsructive sleep apnea.
Date
2014-06-01Author
KıSKAÇ, MUHARREMARDIC, C
CIKRIKCIOGLU, M
KART, L
ZORLU, MEHMET
AKKOYUNLU, MUHAMMED EMİN
CAMLI, AHMET ADİL
CAKIRCA, MUSTAFA
Karatoprak, CUMALİ
KILIC, ERDEM
YAVUZ, E
Advisor
Type
Metadata
Show full item recordAbstract
Background: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are
ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive
sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to
measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS
and examine the relationship between these two adipocytokines and OSAS.
Methods: The study consisted of two groups: severe OSAS patients with an apnea-hypopnea index (AHI)
of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group,
25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared.
Results: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS
compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13;
P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached
statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17).
Conclusions: We found that serum vaspin levels were significantly lower in patients with severe OSAS
compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in
severe OSAS patients may be important in diagnosis and follow-up of these patients.
Collections
- Diş Hekimliği Fakültesi [183]
- Tıp Fakültesi [2546]
- Yayınlar - Eserler [10028]